Diphtheria toxin conjugate therapy of cancer.

Arthur E. Frankel, Bayard L. Powell, Michael B. Lilly

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The approval by the FDA of ONTAK (DAB389IL2) for CTCL and the encouraging results described above with a number of DT conjugates for different neoplasms suggest that a niche is developing for these biologic agents. Moreover, practicing physicians are becoming more familiar with the side effect profile for these agents, increasing their comfort with using these unique drugs. Finally, the marked synergy observed between standard cytotoxic drugs and other biologics such as Herceptin and Rituximab suggests that similar supra-additive effects may be observed by combining DT conjugates with chemotherapy. In support of this hypothesis, in vitro synergy has been observed between DT388GMCSF and both cytarabine and doxorubicin [84,85]. The future appears to show expanded testing of DT conjugates with likely rapid clinical development, particularly for chemotherapy-resistant hematologic neoplasms and brain tumors.

Original languageEnglish (US)
Pages (from-to)301-313
Number of pages13
JournalCancer chemotherapy and biological response modifiers
Volume20
StatePublished - 2002

Fingerprint

Diphtheria Toxin
Immunotoxins
Drug Therapy
Cytarabine
Biological Factors
Hematologic Neoplasms
Biological Products
Brain Neoplasms
Pharmaceutical Preparations
Doxorubicin
Neoplasms
Physicians
Therapeutics
In Vitro Techniques
Trastuzumab
Rituximab

Cite this

Diphtheria toxin conjugate therapy of cancer. / Frankel, Arthur E.; Powell, Bayard L.; Lilly, Michael B.

In: Cancer chemotherapy and biological response modifiers, Vol. 20, 2002, p. 301-313.

Research output: Contribution to journalArticle

Frankel, Arthur E. ; Powell, Bayard L. ; Lilly, Michael B. / Diphtheria toxin conjugate therapy of cancer. In: Cancer chemotherapy and biological response modifiers. 2002 ; Vol. 20. pp. 301-313.
@article{40447561b0a04eba8678694c655ce394,
title = "Diphtheria toxin conjugate therapy of cancer.",
abstract = "The approval by the FDA of ONTAK (DAB389IL2) for CTCL and the encouraging results described above with a number of DT conjugates for different neoplasms suggest that a niche is developing for these biologic agents. Moreover, practicing physicians are becoming more familiar with the side effect profile for these agents, increasing their comfort with using these unique drugs. Finally, the marked synergy observed between standard cytotoxic drugs and other biologics such as Herceptin and Rituximab suggests that similar supra-additive effects may be observed by combining DT conjugates with chemotherapy. In support of this hypothesis, in vitro synergy has been observed between DT388GMCSF and both cytarabine and doxorubicin [84,85]. The future appears to show expanded testing of DT conjugates with likely rapid clinical development, particularly for chemotherapy-resistant hematologic neoplasms and brain tumors.",
author = "Frankel, {Arthur E.} and Powell, {Bayard L.} and Lilly, {Michael B.}",
year = "2002",
language = "English (US)",
volume = "20",
pages = "301--313",
journal = "Cancer chemotherapy and biological response modifiers",
issn = "0921-4410",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Diphtheria toxin conjugate therapy of cancer.

AU - Frankel, Arthur E.

AU - Powell, Bayard L.

AU - Lilly, Michael B.

PY - 2002

Y1 - 2002

N2 - The approval by the FDA of ONTAK (DAB389IL2) for CTCL and the encouraging results described above with a number of DT conjugates for different neoplasms suggest that a niche is developing for these biologic agents. Moreover, practicing physicians are becoming more familiar with the side effect profile for these agents, increasing their comfort with using these unique drugs. Finally, the marked synergy observed between standard cytotoxic drugs and other biologics such as Herceptin and Rituximab suggests that similar supra-additive effects may be observed by combining DT conjugates with chemotherapy. In support of this hypothesis, in vitro synergy has been observed between DT388GMCSF and both cytarabine and doxorubicin [84,85]. The future appears to show expanded testing of DT conjugates with likely rapid clinical development, particularly for chemotherapy-resistant hematologic neoplasms and brain tumors.

AB - The approval by the FDA of ONTAK (DAB389IL2) for CTCL and the encouraging results described above with a number of DT conjugates for different neoplasms suggest that a niche is developing for these biologic agents. Moreover, practicing physicians are becoming more familiar with the side effect profile for these agents, increasing their comfort with using these unique drugs. Finally, the marked synergy observed between standard cytotoxic drugs and other biologics such as Herceptin and Rituximab suggests that similar supra-additive effects may be observed by combining DT conjugates with chemotherapy. In support of this hypothesis, in vitro synergy has been observed between DT388GMCSF and both cytarabine and doxorubicin [84,85]. The future appears to show expanded testing of DT conjugates with likely rapid clinical development, particularly for chemotherapy-resistant hematologic neoplasms and brain tumors.

UR - http://www.scopus.com/inward/record.url?scp=0038315196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038315196&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 301

EP - 313

JO - Cancer chemotherapy and biological response modifiers

JF - Cancer chemotherapy and biological response modifiers

SN - 0921-4410

ER -